Repligen | RGEN - Cash And Equivalent


Repligen reported $566.02M in Cash and Equivalent for its fiscal quarter ending in December of 2025.





Cash And Equivalent Change Date
Agilent USD 1.76B 31M Dec/2025
Align Technology USD 1B 103.43M Sep/2025
Bio Techne USD 172.88M 27.92M Dec/2025
BioMarin Pharmaceutical USD 1.31B 61.57M Dec/2025
Bristol-Myers Squibb USD 10.21B 5.52B Dec/2025
Bruker USD 293.1M 201.1M Sep/2025
Charles River Laboratories USD 213.77M 6.67M Dec/2025
Danaher USD 5.7B 1.09B Mar/2026
Dentsply International USD 326M 37M Dec/2025
General Electric Aerospace USD 10.98B 1.41B Mar/2026
Henry Schein USD 136M 9M Sep/2025
Illumina USD 1.42B 368M Dec/2025
IQVIA Holdings USD 1.98B 166M Dec/2025
Mettler Toledo International USD 69.06M 7.24M Sep/2025
Myriad Genetics USD 149.6M 4.2M Dec/2025
OraSure Technologies USD 199.28M 17.2M Dec/2025
Pacific Biosciences Of California USD 279.51M 223.04M Dec/2025
Pfizer USD 1.34B 295M Sep/2025
Repligen USD 566.02M 182.73M Dec/2025
Revvity USD 919.86M 11.53M Dec/2025
Standard Biotools USD 118.21M 11.2M Dec/2025
Thermo Fisher Scientific USD 3.25B 6.6B Mar/2026
Waters USD 587.83M 128.71M Dec/2025
West Pharmaceutical Services USD 521.4M 269.9M Mar/2026